

## KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LIMITED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2023

(Rupees in Lakhs)

	(Rupees in			
123	Particulars	Note no.	For the year ended	For the year ended
	\$1.44 f 1874[\$3] [YEN] 3 VI DAW [\$39] [\$3] [B. [B. [B. [S]]		31 March 2023	31 March 2022
	REVENUE:			
1	Revenue from operations	24	52889.66	47532.24
11	Other Income	25	749.68	392.16
Ш	Total Income (I + II)		53639.34	47924.40
IV	EXPENSES:			
	Cost of materials consumed	26	22973.60	21796.53
	Purchases of Stock-in-Trade		6326 02	5001.08
	Changes in inventories of finished goods, work in progress and stock-in-trade	27	(377.13)	(602,65)
	Emloyee benefits expense	28	8049.24	7208.28
	Finance Costs	29	587,88	107_42
	Depreciation and amortisation expense	30	757.19	813,95
	Other expenses	31	11897.14	10348.17
	Total Expenses (IV)		50213.94	44672.78
V VI	Profit before exceptional items and tax (III-IV) Exeptional Item		3425.40	3251.62
VII	Profit before tax (V - VI)		3425.40	3251.62
VIII	Tax expense		0.125.10	5251,02
	a) Current tax		876.47	953_18
	b) Deferred Tax		117 49	(167.14)
	c) Tax adjustment for earlier years	1	(57,35)	(0.24)
	Total Tax expense		936.61	785.80
X	Profit for the year (VII-VIII)		2488.79	2465.82
ζ.	Other comprehensive income	32		
	A (i) Items that will not be reclassified to profit or loss		0.68	(65.76)
	(ii) Income tax relating to items that will not be reclassified to profit or loss		(0.17)	16.55
	(ii) medice tax retaining to items that will not be reclassified to profit of loss	-		
a	Total comprehensive income for the year (IX + X)	A SULTANIA	0.51 2489.30	(49.21) 2416.61
(H	Earnings per equity share of Rs 100/- each		2.107.369	2110.01
	Basic and Diluted	36	184.49	182.79
ianifi	cant Accounting Policies and accompanying Notes No. 1 to 50 form an integral no			.02.72

Significant Accounting Policies and accompanying Notes No. 1 to 50 form an integral part of the Financial Statements

This is the Statement of Profit and Loss referred

CHENNAL

600 042

to in Audit Report of even date

For YOGANANDH & RAM LLP

Chartered Accountants FRN: 005157S/S200052

Manoj Kumar Jain

Partner

Membership No. 218610

Date: 18th July 2023 Place: Bengaluru

For and on behalf of Board of Directors of

Karnatak Antibiotics and Pharmaceuticals Ltd CIN: U2423 IKA1981GOI004145

Sunil Kumar Kaimal

Managing Director

DIN:08528088

Jagadish C

Deputy General Manager- Finance

Dr.Madhuchanda Kar

MKar

Independent Director

DIN:09519016

Supriya Kulkarni Company Secretary

